Searched for
PERIN ALI ANALYST
Will Ranbaxy Labs be the next turnaround story?Hopes of settlement with US Food and Drug Administration, a strong product pipeline & a discounted P/E make Ranbaxy Laboratories attractive.- Aurobindo at a record high, price-to-earnings at 32% discount to peersFor the next fiscal, the stock is trading at 8.7 times to its P/E multiple compared with an average 15.3 times, which is at a 52% discount ...
- Slowdown hits domestic pharma, market shrinks 1.8 per cent in SeptemberThe economic slowdown has hit the Rs 72,000- crore domestic pharma business, usually considered recession-proof.
- Dr Reddy's, Merck to jointly develop biosimilarsmanufacturing of the compounds and will lead phase-III development.
Load More- Dr Reddy's, Merck to jointly develop biosimilars